Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for rhinitis.

Hans-Jørgen Malling1

  • 1Allergy Clinic 4222, National University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. all-unit@rh.dk

Current Allergy and Asthma Reports
|March 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hymenoptera venom allergy].

Ugeskrift for laeger·2025
Same author

ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

Clinical and translational allergy·2021
Same author

[Anaphylaxis in children and adults].

Ugeskrift for laeger·2020
Same author

2019 ARIA Care pathways for allergen immunotherapy.

Allergy·2019
Same author

Proficiency testing of skin prick testers as part of a quality assurance system.

Clinical and translational allergy·2016
Same author

[Anaphylaxis].

Ugeskrift for laeger·2015

Allergen-specific immunotherapy effectively reduces allergic rhinitis symptoms and medication needs, offering long-term benefits and potentially preventing asthma development.

Area of Science:

  • Immunology
  • Allergology
  • Otolaryngology

Background:

  • Allergic rhinitis significantly impacts quality of life and necessitates effective treatments.
  • Current pharmacotherapy offers symptomatic relief but does not address underlying immune dysregulation.

Purpose of the Study:

  • To evaluate the clinical efficacy and immunomodulatory effects of allergen-specific immunotherapy (AIT) for allergic rhinitis.
  • To compare AIT with standard anti-allergic pharmacotherapy.
  • To explore the long-term and preventive potential of AIT.

Main Methods:

  • Systematic review and meta-analysis of published clinical trials.
  • Assessment of symptom scores, medication usage, and quality of life.
  • Analysis of immunological markers, including Th1 cytokine profiles and allergic phenotype downregulation.

Related Experiment Videos

Main Results:

  • AIT demonstrates statistically significant and clinically relevant reductions in allergic rhinitis symptom scores and pharmacotherapy requirements.
  • The efficacy of AIT is comparable or superior to conventional anti-allergic drugs.
  • AIT induces a Th1 cytokine profile, downregulates the allergic phenotype, and shows potential for long-term disease control and prevention of asthma progression.

Conclusions:

  • Allergen-specific immunotherapy is a highly effective treatment for allergic rhinitis with significant clinical benefits.
  • AIT offers immunomodulatory advantages, including long-term efficacy and potential to prevent the development of asthma.
  • Subcutaneous immunotherapy is recommended for severe cases with bronchial hyperreactivity, while sublingual immunotherapy suits milder conditions.